2025 Q4 -tulosraportti
Vain PDF
20 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sittenThis is what they can do tomorrow, so appointments can be made here:) 1x1 meeting 26th Bio€quity Europe May 4-6, 2026 | Prague, Czech Republic A Presenter slot at Bio€quity Europe is: €4,869 until April 2, 2026 €5,868 after April 2, 2026 What's Included Access to presenting company perks like an exclusive pitch deck optimization webinar from LifeScience ORG A live corporate presentation of 12 minutes, plus Q&A, introduced and moderated by an investor All access pass to the conference (valued at €3,300) One presentation slot Access to our partnering platform to schedule 1x1 meetings An invitation for CEO to join an exclusive Presenting Company CEO and Investor ONLY networking reception Ability to post a pre-recorded video presentation to the partnering platform
·9 t sittenCame across this job posting on LinkedIn recently. Circio is now looking for a "Postdoctoral Immunologist" for its R&D team in Stockholm. This is interesting for two reasons: 1 Strategic confirmation: The ad specifically requests expertise in T-cell biology and LNP delivery (lipid nanoparticles). This directly aligns with the recently announced agreement with Acuitas Therapeutics, which is precisely about delivering circVec to T-cells using LNP. 2 Preparing for growth: The fact that the company is hiring for scientific leadership positions in the run-up to the Boston conference (ASGCT) next week suggests that they are now moving from pure technology development to active work on drug candidates. It also confirms that the company has the financial backbone needed to expand the team. Although warrants and dilution characterize the short-term share price, it is positive to see that the operational work behind the scenes continues with undiminished strength.
10 t sitten10 t sittenI think that @bennyz “broken door” drama is more exciting than the upcoming presentations 💋🫦⛓️💥 😈 That said, unless these upcoming May meetings actually translate into tangible positive news or catalysts, I don’t expect them to move the stock meaningfully. Presentations alone rarely shift sentiment unless they bring new data, partnerships, or clear commercial progress. 🫦🤷🏻♀️🏳️⚧️ Bring some balls @bennyz! 😎 To be honest, from a purely strategic angle, my other biotech bet, AgomAb Therapeutics, currently looks better positioned from an acquisition standpoint than Circio — at least based on pipeline maturity and broader market traction, but that’s still speculative for both! 🙄 That said, Circio is a Norwegian innovation, and I’m still backing it. #NotLosingHope 🫶 🇳🇴
·5 t sittenSimply Wall St values it at 1 NOK No positive remark Risk Analysis Negative shareholders equity Shareholders have been substantially diluted in the past year Highly volatile share price over the past 3 months compared to the Norwegian market But AgomAb Therapeutics is more attractive Simply Wall St values it at 32 USD Rewards Analysts in good agreement that stock price will rise by 164.4% Risk Analysis Earnings are forecast to decline by an average of 18.6% per year for the next 3 years Currently unprofitable and not forecast to become profitable over the next 3 years·26 min sittenSimply Wall St performs poorly on such early biotech/platform cases. That model penalizes Circio for negative equity, dilution, volatility, and lack of earnings, which is correct in isolation. But it can hardly price the value of circVec, pharma collaboration, ASGCT, in vivo data, and possible license/acquisition.
·12 t sitten*10 most bought shares in April - Circio 5th place Not primarily as either hyping or a buy recommendation, but a factual statement. Has probably been mentioned before, but. Well worth noting that Circio is by far the "smallest" stock here, i.e. in price. Norwegian is closest with a price of approx 14,6 kr +-. Something must be done right in "little" Circio when they are on such a list. Exciting times. Come May, you beautiful mild one🌻
·12 t sitten🧬 WE RISE AGAIN 🧬 That Circio fell about 4 percent today is harmless. A little price fluctuation now is normal. The case is unchanged – and we are in an exciting period. We are now in the middle of BioEquity 2026 in Prague (May 4–6) – an important meeting place for investors and Big Pharma. Here, relationships will be built and more interest will be created around Circio, circVec and mRNA technology. This rarely yields immediate news, but can lay the groundwork for future collaborations and agreements. My assessment is that Circio is gaining momentum, and we will go up past the issue price! May is and will be an incredibly exciting month🚀 * May 8, 2026: General Assembly in Oslo, Norway * May 11–15, 2026: ASGCT in Boston, USA * May 26–28, 2026: Circular & Self-Amplifying RNA Therapeutics Summit in Boston, USA I am holding on🚂
·9 t sittenAgreed, up towards the issue price. I think the price for the share today is between 9-11kr. Meaning that it is positioned well right now and will rise as the company's exposure increases and positive results continuously come in. The CEO has full focus on verification and value creation with technology and the best expertise. 14,40 can be broken during May.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
20 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenThis is what they can do tomorrow, so appointments can be made here:) 1x1 meeting 26th Bio€quity Europe May 4-6, 2026 | Prague, Czech Republic A Presenter slot at Bio€quity Europe is: €4,869 until April 2, 2026 €5,868 after April 2, 2026 What's Included Access to presenting company perks like an exclusive pitch deck optimization webinar from LifeScience ORG A live corporate presentation of 12 minutes, plus Q&A, introduced and moderated by an investor All access pass to the conference (valued at €3,300) One presentation slot Access to our partnering platform to schedule 1x1 meetings An invitation for CEO to join an exclusive Presenting Company CEO and Investor ONLY networking reception Ability to post a pre-recorded video presentation to the partnering platform
- ·9 t sittenCame across this job posting on LinkedIn recently. Circio is now looking for a "Postdoctoral Immunologist" for its R&D team in Stockholm. This is interesting for two reasons: 1 Strategic confirmation: The ad specifically requests expertise in T-cell biology and LNP delivery (lipid nanoparticles). This directly aligns with the recently announced agreement with Acuitas Therapeutics, which is precisely about delivering circVec to T-cells using LNP. 2 Preparing for growth: The fact that the company is hiring for scientific leadership positions in the run-up to the Boston conference (ASGCT) next week suggests that they are now moving from pure technology development to active work on drug candidates. It also confirms that the company has the financial backbone needed to expand the team. Although warrants and dilution characterize the short-term share price, it is positive to see that the operational work behind the scenes continues with undiminished strength.
- 10 t sitten10 t sittenI think that @bennyz “broken door” drama is more exciting than the upcoming presentations 💋🫦⛓️💥 😈 That said, unless these upcoming May meetings actually translate into tangible positive news or catalysts, I don’t expect them to move the stock meaningfully. Presentations alone rarely shift sentiment unless they bring new data, partnerships, or clear commercial progress. 🫦🤷🏻♀️🏳️⚧️ Bring some balls @bennyz! 😎 To be honest, from a purely strategic angle, my other biotech bet, AgomAb Therapeutics, currently looks better positioned from an acquisition standpoint than Circio — at least based on pipeline maturity and broader market traction, but that’s still speculative for both! 🙄 That said, Circio is a Norwegian innovation, and I’m still backing it. #NotLosingHope 🫶 🇳🇴·5 t sittenSimply Wall St values it at 1 NOK No positive remark Risk Analysis Negative shareholders equity Shareholders have been substantially diluted in the past year Highly volatile share price over the past 3 months compared to the Norwegian market But AgomAb Therapeutics is more attractive Simply Wall St values it at 32 USD Rewards Analysts in good agreement that stock price will rise by 164.4% Risk Analysis Earnings are forecast to decline by an average of 18.6% per year for the next 3 years Currently unprofitable and not forecast to become profitable over the next 3 years·26 min sittenSimply Wall St performs poorly on such early biotech/platform cases. That model penalizes Circio for negative equity, dilution, volatility, and lack of earnings, which is correct in isolation. But it can hardly price the value of circVec, pharma collaboration, ASGCT, in vivo data, and possible license/acquisition.
- ·12 t sitten*10 most bought shares in April - Circio 5th place Not primarily as either hyping or a buy recommendation, but a factual statement. Has probably been mentioned before, but. Well worth noting that Circio is by far the "smallest" stock here, i.e. in price. Norwegian is closest with a price of approx 14,6 kr +-. Something must be done right in "little" Circio when they are on such a list. Exciting times. Come May, you beautiful mild one🌻
- ·12 t sitten🧬 WE RISE AGAIN 🧬 That Circio fell about 4 percent today is harmless. A little price fluctuation now is normal. The case is unchanged – and we are in an exciting period. We are now in the middle of BioEquity 2026 in Prague (May 4–6) – an important meeting place for investors and Big Pharma. Here, relationships will be built and more interest will be created around Circio, circVec and mRNA technology. This rarely yields immediate news, but can lay the groundwork for future collaborations and agreements. My assessment is that Circio is gaining momentum, and we will go up past the issue price! May is and will be an incredibly exciting month🚀 * May 8, 2026: General Assembly in Oslo, Norway * May 11–15, 2026: ASGCT in Boston, USA * May 26–28, 2026: Circular & Self-Amplifying RNA Therapeutics Summit in Boston, USA I am holding on🚂·9 t sittenAgreed, up towards the issue price. I think the price for the share today is between 9-11kr. Meaning that it is positioned well right now and will rise as the company's exposure increases and positive results continuously come in. The CEO has full focus on verification and value creation with technology and the best expertise. 14,40 can be broken during May.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
20 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sittenThis is what they can do tomorrow, so appointments can be made here:) 1x1 meeting 26th Bio€quity Europe May 4-6, 2026 | Prague, Czech Republic A Presenter slot at Bio€quity Europe is: €4,869 until April 2, 2026 €5,868 after April 2, 2026 What's Included Access to presenting company perks like an exclusive pitch deck optimization webinar from LifeScience ORG A live corporate presentation of 12 minutes, plus Q&A, introduced and moderated by an investor All access pass to the conference (valued at €3,300) One presentation slot Access to our partnering platform to schedule 1x1 meetings An invitation for CEO to join an exclusive Presenting Company CEO and Investor ONLY networking reception Ability to post a pre-recorded video presentation to the partnering platform
- ·9 t sittenCame across this job posting on LinkedIn recently. Circio is now looking for a "Postdoctoral Immunologist" for its R&D team in Stockholm. This is interesting for two reasons: 1 Strategic confirmation: The ad specifically requests expertise in T-cell biology and LNP delivery (lipid nanoparticles). This directly aligns with the recently announced agreement with Acuitas Therapeutics, which is precisely about delivering circVec to T-cells using LNP. 2 Preparing for growth: The fact that the company is hiring for scientific leadership positions in the run-up to the Boston conference (ASGCT) next week suggests that they are now moving from pure technology development to active work on drug candidates. It also confirms that the company has the financial backbone needed to expand the team. Although warrants and dilution characterize the short-term share price, it is positive to see that the operational work behind the scenes continues with undiminished strength.
- 10 t sitten10 t sittenI think that @bennyz “broken door” drama is more exciting than the upcoming presentations 💋🫦⛓️💥 😈 That said, unless these upcoming May meetings actually translate into tangible positive news or catalysts, I don’t expect them to move the stock meaningfully. Presentations alone rarely shift sentiment unless they bring new data, partnerships, or clear commercial progress. 🫦🤷🏻♀️🏳️⚧️ Bring some balls @bennyz! 😎 To be honest, from a purely strategic angle, my other biotech bet, AgomAb Therapeutics, currently looks better positioned from an acquisition standpoint than Circio — at least based on pipeline maturity and broader market traction, but that’s still speculative for both! 🙄 That said, Circio is a Norwegian innovation, and I’m still backing it. #NotLosingHope 🫶 🇳🇴·5 t sittenSimply Wall St values it at 1 NOK No positive remark Risk Analysis Negative shareholders equity Shareholders have been substantially diluted in the past year Highly volatile share price over the past 3 months compared to the Norwegian market But AgomAb Therapeutics is more attractive Simply Wall St values it at 32 USD Rewards Analysts in good agreement that stock price will rise by 164.4% Risk Analysis Earnings are forecast to decline by an average of 18.6% per year for the next 3 years Currently unprofitable and not forecast to become profitable over the next 3 years·26 min sittenSimply Wall St performs poorly on such early biotech/platform cases. That model penalizes Circio for negative equity, dilution, volatility, and lack of earnings, which is correct in isolation. But it can hardly price the value of circVec, pharma collaboration, ASGCT, in vivo data, and possible license/acquisition.
- ·12 t sitten*10 most bought shares in April - Circio 5th place Not primarily as either hyping or a buy recommendation, but a factual statement. Has probably been mentioned before, but. Well worth noting that Circio is by far the "smallest" stock here, i.e. in price. Norwegian is closest with a price of approx 14,6 kr +-. Something must be done right in "little" Circio when they are on such a list. Exciting times. Come May, you beautiful mild one🌻
- ·12 t sitten🧬 WE RISE AGAIN 🧬 That Circio fell about 4 percent today is harmless. A little price fluctuation now is normal. The case is unchanged – and we are in an exciting period. We are now in the middle of BioEquity 2026 in Prague (May 4–6) – an important meeting place for investors and Big Pharma. Here, relationships will be built and more interest will be created around Circio, circVec and mRNA technology. This rarely yields immediate news, but can lay the groundwork for future collaborations and agreements. My assessment is that Circio is gaining momentum, and we will go up past the issue price! May is and will be an incredibly exciting month🚀 * May 8, 2026: General Assembly in Oslo, Norway * May 11–15, 2026: ASGCT in Boston, USA * May 26–28, 2026: Circular & Self-Amplifying RNA Therapeutics Summit in Boston, USA I am holding on🚂·9 t sittenAgreed, up towards the issue price. I think the price for the share today is between 9-11kr. Meaning that it is positioned well right now and will rise as the company's exposure increases and positive results continuously come in. The CEO has full focus on verification and value creation with technology and the best expertise. 14,40 can be broken during May.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt